Crispr Therapeutics is trading at $49.00 (down 4.6%) as the stock continues a multi-day slide driven by broader biotech sector headwinds and valuation concerns.
- The recent decline follows a period of persistent weakness starting in early July, with shares falling from levels above $60.00.
- Market analysts suggest the move is part of ongoing volatility within the gene-editing space rather than a reaction to fresh company-specific news.
- The stock remains under pressure as investors reassess valuations across the biotech industry amid broader market volatility.